Shire Provides Results For Phase 3b Vyvanse Study Pharmaceutical Business Review Vyvanse is currently approved by the FDA for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD. The study supports the results of ... VYVANSE CII Provided Significant Efficacy At 14 Hours After ... Medical News Today (press release) all 3 news articles »

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided ... PR Newswire (press release) VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New ... and more »

World-renowned child psychiatrists and psychologists from The Child Study Center at NYU Langone Medical Center tackle the most important issues kids and parents face today Expert advice and tips on how to deal with issues such as Autism, ADHD, mood disorders, depression, anxiety, homosexuality and more explored on marathon of Doctor Radio's weekly child psych show NEW YORK, July 1 /PRNewswire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI) today announced it will broadcast a July 4th family speci

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided ... PR Newswire (press release) VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New ... and more »

Placebo Effects In Caregivers May Change Behavior Of Children With ... Science Daily (press release) In this case, the review suggested that when caregivers believed their ADHD patients were receiving ADHD medication, they tended to view those children more ... ADHD drug in kid, placebo effect in adults United Press International all 9 news articles »